This program is now available in English as well.

REHACOG is a neuropsychological rehabilitation programme based on a scientifically proven methodology and with multiple evidences of its efficacy, which acts at a preventive level to slow down possible cognitive deterioration.

 The programme is a comprehensive rehabilitation tool that improves cognition, functionality and quality of life in the elderly, preventing cognitive deterioration leading to the development of dementia.

It is the result of the work of several specialists in neuropsychology with more than 20 years of experience in the field.

Who is it designed for?

It is the adaptation of RehacoP to people over 55 years of age with or without cognitive impairment.

  • It has been used in:
  • Healthy population to prevent cognitive impairment 
  • Patients with Mild Cognitive Impairment
  • Parkinson’s Disease Patients 
  • Multiple Sclerosis Patients

It is a comprehensive and structured programme with 11 work modules:

  • Reality orientation Psychomotor skills Attention
  • Calculation Memory Language
  • Executive Functions 
  • Social Cognition
  •  Social Skills
  •  Everyday Activities
  •  Psychoeducation

It consists of more than 500 rehabilitation exercises, easy to administer with instructions, guidelines for assessing change, follow-up sheets and suggestions for home exercises.

The exercises are structured by cognitive sub-domain and level of difficulty. It includes recommendations and guidance on how to assess change or improvement, or how to collect and use information in working sessions with patients. The materials are practical, in colour, and include instructions for patients and solutions for the therapist.

It can be used in individual or group sessions, and it is recommended that the therapist be a person trained in neuropsychology.

Its efficacy has been tested with several populations and as a result, there are already several national and international scientific publications in journals of high scientific impact. The programme is currently being tested in other clinical populations.

Its official public presentation took place in February 2017 in the context of the 23rd National Congress of Psychogeriatrics in Bilbao.